Molecule intelOpportunity: ModerateEssential

Irinotecan

31 brands · 22 companies · product forms

ATC: L01CE02

Opportunity snapshot

Launch attractiveness
44
Market saturation
57
Price room
100
Regulatory risk
0
31
brands
22
companies
Rs 12,127.45
median price
30
price points
5.72x
price spread
100
confidence %

Who competes here

Top companies by brand count — fragmented market (no dominant player) · leader share 13%

Price room

Across observed sources and strengths
CheapestRs 4,933.62
MedianRs 12,127.45
Most expensiveRs 28,215.44
Spread5.72×
Sources: DRAP-official

max/min price ratio 5.72x across 30 trusted points (Rs 4933.62-28215.44). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Brands & products on the market

Sample of 12 live products for Irinotecan — each links to its own medicine page.

Why this score

Launch attractiveness

40% supply-gap(25) + 25% price-variation(100) + 20% low-competition(43) + 15% supply-disruption(0), damped by confidence(100). Higher = more attractive, less crowded opportunity.

Market saturation

22 canonical companies and 31 brands compete (saturation pegged at 30 companies / 150 brands).

Price room

max/min price ratio 5.72x across 30 trusted points (Rs 4933.62-28215.44). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Regulatory risk

No DRAP alerts on this molecule's brands.

Confidence

Full coverage.

Packaged brief for this moderate opportunity?

Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.

See packaged reports All 3868 molecules

Molecule intelligence as of 2026-07-30. Brand/company counts from DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.